Order Article Reprints

Zhao D, Li H, Mambetsariev I, Mirzapoiazova T, Chen C, Fricke J, Kulkarni P, Villaflor V, Arvanitis L, Hamilton S, et al. Clinical and Molecular Features of KRAS-Mutated Lung Cancer Patients Treated with Immune Checkpoint Inhibitors. Cancers. 2022; 14(19):4933. https://doi.org/10.3390/cancers14194933

Zhao, Dan, Haiqing Li, Isa Mambetsariev, Tamara Mirzapoiazova, Chen Chen, Jeremy Fricke, Prakash Kulkarni, Victoria Villaflor, Leonidas Arvanitis, Stanley Hamilton, and et al. 2022. "Clinical and Molecular Features of KRAS-Mutated Lung Cancer Patients Treated with Immune Checkpoint Inhibitors" Cancers 14, no. 19: 4933. https://doi.org/10.3390/cancers14194933

Zhao, D., Li, H., Mambetsariev, I., Mirzapoiazova, T., Chen, C., Fricke, J., Kulkarni, P., Villaflor, V., Arvanitis, L., Hamilton, S., Afkhami, M., Pillai, R., Armstrong, B., Erhunmwunsee, L., Massarelli, E., Sattler, M., Amini, A., & Salgia, R. (2022). Clinical and Molecular Features of KRAS-Mutated Lung Cancer Patients Treated with Immune Checkpoint Inhibitors. Cancers, 14(19), 4933. https://doi.org/10.3390/cancers14194933